All News
Anti-Drug Antibodies and Biologic Drug Responses
A prospective cohort study suggests the presence of antidrug antibodies may be associated with bDMARDs nonresponse in rheumatoid arthritis (RA). Should we be monitoring ADAbs (especially in nonresponders)?
Read Article
New therapeutic approach for the treatment of sarcoidosis
Eureka Alert!
A research team led by Georg Stary (Medical University of Vienna and CeMM) has identified a new approach to treating the inflammatory disease sarcoidosis. In a clinical study, the inhibition of a specific signaling pathway showed clear success in the treatment of granulomas in the skin. This opens up new therapeutic paths for sarcoidosis and similar inflammatory diseases. The results were recently published in the journal Lancet Rheumatology.
Read Article
Dr. Strober's JAKi in dermatology takeaways!
- Consider this for AD
- Dose matters in terms of both efficacy and toxicity
- Consider combination tx
- Topical JAKi option for vitiligo, especially head and neck involvement (harder in hands and other areas)
#RNL2024 @RheumNow https://t.co/ZrPfpUF4Hz
Dr. Rachel Tate uptoTate ( View Tweet)
JAKi are being used in inflammatory skin disease other than psoriasis:
#HydradenitisSuppurativa, #alopecia, #AtopicDermatitis and #vitiligo
- Dr. B Strober #RNL2024 @rheumnow https://t.co/FzPyATPB93
TheDaoIndex KDAO2011 ( View Tweet)
Face and neck vitiligo also responds to topical ruxolitinib. Dr. Strober #RNL2024 @RheumNow https://t.co/6N6A3Yq7RE
Dr. Rachel Tate uptoTate ( View Tweet)
Impressive results for alopecia totalis with baricitinib – Dr. Bruce Strober #RNL2024 @rheumnow https://t.co/OA0tpdRum2
Links:
TheDaoIndex KDAO2011 ( View Tweet)
Clinical pearl! Consider topical ruxolitinib for your AD patients. Dr. Strober at #RNL2024 @RheumNow https://t.co/Sxwvn1lAXB
Dr. Rachel Tate uptoTate ( View Tweet)
Deucravacitinib takes longer to work for PsO compared to UPA, IL-17i or IL23i; it’s better than apremilast. Side effects w/TYK2i: acne, mild⬆️CK, but zoster & lipid issues aren't seen much, & no CV risk warnings; Dr. Strober doesn't follow labs w/TYK2i. #RNL2024 @rheumnow https://t.co/05jKqL4wdx
TheDaoIndex KDAO2011 ( View Tweet)
Clinical pearl from #RNL2024 @RheumNow
Palmoplantar psoriasis is a great time for first-line JAK inhibitor - Ben Strober, Yale dermatology
JAK for atopic dermatitis - extremely rapid responses https://t.co/hHYdGl51n2
Links:
Eric Dein ericdeinmd ( View Tweet)
#RNL2024 @RheumNow
Bruce Strober on JAK in skin diseases - diverse benefits:
- PsO
- Atopic dermatitis
- Alopecia areata
- Hidradenitis suppurativa
- Vitiligo
- Lichen planus any many others https://t.co/I9XHVbFpvQ
Eric Dein ericdeinmd ( View Tweet)
More evidence to support role of Tyk2 in management
of skin psoriasis.
Dr.April Armstrong
#RNL2024
@RheumNow https://t.co/9vuuhJMj36
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Nice summary of data as to why IL-17 or IL-23 are generally favoured by dermatology for psoriasis @_AprilArmstrong @RheumNow #RNL2024 https://t.co/qfAn2AHilX
Richard Conway RichardPAConway ( View Tweet)
Dr. A. Armstrong's Key Takeaways for PsO.
TNFi - great in PsA and pregnancy
IL-17i - robust PsO efficacy and in PsA
IL-23i - robust in PsO, fewer injections, and efficacious in PsA.
#RNL2024 @RheumNow @_AprilArmstrong https://t.co/j8LaOGITuf
Dr. Rachel Tate uptoTate ( View Tweet)
Did you know of all the small oral molecules, #apremilast is the only one approved for all stages of #psoriasis (mild to severe)? - Dr. Armstrong polls the audience on their thoughts then revealing the correct answer #RNL2024 @rheumnow https://t.co/NXSiaaGp3p
TheDaoIndex KDAO2011 ( View Tweet)
Dr. A. Armstrong shares dermatology/dermatologist trends in PsO.
1. They tend to shorted then interval between injections as opposed to the amount of medication per dose.
2. Derms generally wait 6 months to switch meds
3. Like rheums, derms tend to switch classes (of tx agent)… https://t.co/HWbJMwnwkE https://t.co/bgKw7ynANN
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
When it comes to skin, this is how derms think and there is data to support this. - Dr. Amstrong on how IL-17i and IL23i are preferred over TNFi #psoriasis #RNL2024 @rheumnow https://t.co/UZWNgOljRh
TheDaoIndex KDAO2011 ( View Tweet)
Dermatologic approach to choosing treatment in psoriatic disease. The presence of psoriatic arthritis is an initial branch point and why co-management is so crucial in these patients @_AprilArmstrong @RheumNow #RNL2024 https://t.co/m26WiEUmPI
Richard Conway RichardPAConway ( View Tweet)
#RNL2024 @RheumNow
@_AprilArmstrong
Bimekizumab: IL-17A and IL-17F dual efficacy, unlike the prior IL-17i drugs
- Fast onset
- High efficacy with 2/3 PASI 100 by wk 16 (BE READY) https://t.co/cKh7j4KBs9
Eric Dein ericdeinmd ( View Tweet)
How/when to choose biologics in pts with active psoriasis from Dr April Armstrong #rnl2024
Dr. John Cush RheumNow ( View Tweet)
#RNL2024 @RheumNow
TREAT-EARLIER - MTX for Clinically Suspect Arthralgias
No overall diff vs PBO
High risk pts had benefit, but not sustained at 2 yrs
But sustained reduction in HAQ & MRI inflammation
- Signs for hope? Overall, prevention studies have been disappointing https://t.co/DtBlGaw0Lf
Links:
Eric Dein ericdeinmd ( View Tweet)
